Category IP Policies

Key US Senators Warn Bush Administration On ACTA

By William New The leaders of the powerful United States Senate Judiciary Committee on Thursday warned US trade negotiators to rein in the scope of negotiations on an international treaty against counterfeiting, and to make the process more transparent. At…

Economic Crisis Sends IP Owners (And Their Lawyers) Looking For Protection

By Liza Porteus Viana for Intellectual Property Watch
NEW YORK - As the value of intellectual property increases in the innovation economy, an increasing number of IP owners are trying to guard their ideas and innovations through business-method patents, international trade agreements, biological patents and other forms of protection.

But amid the economic crisis roiling the financial markets around the world and trickling down to Main Street, intellectual property owners often need to weigh the costs and benefits of protecting their IP assets through litigation. Many companies say it is hard-knock times like these that make protecting their intellectual property even more vital.

Optimism Reigns As WIPO Assemblies Close, Gurry Takes Office

By William New Member governments of the UN World Intellectual Property Organization concluded this year’s annual assemblies with high optimism for the future of the intellectual property system and for the organisation. “We’re glad to see WIPO back to its…

الخبراء يجتمعون لمناقشة دور الملكية الفكرية في نقل التكنولوجيا البيئية

بقلم كيتلن مارا تزداد أهمية نقل التكنولوجيا مع تزايد أهمية التكنولوجيا في الاقتصاد العالمي. وفي حالة تصدي التكنولوجيا للمشاكل البيئية، قد يكون هذا النقل متكاملاً لضمان قدرة البلدان النامية على اتخاذ تدابير المحافظة. واجتمعت مجموعة متنوعة من الخبراء هذا الأسبوع…

Biotech, Pharma Industries To Target IP Protection Legislation, Patent Reform

By Liza Porteus Viana for Intellectual Property Watch
When the new administration and Congress come into office following the November elections in the United States, the pharmaceutical and biotechnology industries will prioritise protection of their intellectual property and innovative biological drugs as the push for cheaper, generic versions gets stronger. Patent reform also will continue to be a lobbying priority, as well as making sure intellectual property is protected in any forthcoming international trade agreements.